GSK Q1 2024 Revenue Soars on Strong Vaccine Sales: Shingrix Hits $1.18B, Arexvy RSV Vaccine Reaches $228M
GSK
Pharmaceutical R&D Manufacturer
On May 1, 2024, GSK released its Q1 financial report, with revenue of £7.367 billion, a year-on-year increase of 10%. Excluding the impact of COVID-19 products, the year-on-year growth was 13%.
GSK's Q1 2024 Vaccine Business: Respiratory RSV Vaccine Arexvy Grows 22%, Shingles Vaccine Shingrix Sets Sales Record! Vaccine Business Becomes the Core Growth Driver of GSK's Performance.Shingles vaccine sales reached £945 million, equivalent to $1.18 billion, representing an 18% year-over-year increase; RSV vaccine sales amounted to £182 million, or $228 million.
The herpes zoster vaccine is sold in 39 markets outside the United States, with penetration rates below 5% in most markets, but vaccination rates among American adults are...The penetration rate of the Shingrix vaccine is approximately 37%, with annual sales projected to reach $4 billion by 2026.Meningitis vaccine increased by 11%, flu vaccine increased by 8%, and other vaccines increased by 7%.
RSV Vaccine Arexvy Launched in 24 Markets Outside the U.S., with 1.3 Million People Receiving the Vaccine in Q1 2024 and 7 Million Since Its Launch in May 2023. Sales Peak Expected to Exceed £3 Billion!
2024-2025Upcoming pipeline catalysts, GSK's main vaccine pipeline is as follows:
GSK's Revenue Details for Q1 2024 are as Follows:
